Company intelligence / Profile preview
Neurocrine Biosciences
San Diego, California, United Statesneurocrine.com ↗
- Ownership
- Public · NBIX
- Employees
- ~1700
- Development stage
- Other
01
Overview
Neurocrine has FDA-approved treatments for tardive dyskinesia (INGREZZA), Huntington's disease chorea, congenital adrenal hyperplasia (CRENESSITY), endometriosis and uterine fibroids. The company received FDA approval for CRENESSITY (crinecerfont) in December 2024 and is advancing multiple mid-to-late phase clinical programs[1][2][3].
- Therapeutic areas
- Women's HealthEndocrinologyPsychiatryNeurology
- Modalities
- Small moleculesbiologics
- Industry
- Biotech
02
Drug pipeline
36 assets35 more assets in the full pipeline.
03
Partnerships
AbbVieTakedaMitsubishi Tanabe PharmaNxera PharmaPANTHERx Rare
04
Financials
- Market cap
- $16.2B
- Total revenue
- $2.9B
- Enterprise value
- $15.8B
Beyond the preview
Go deeper on Neurocrine Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurocrine Biosciences.